secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edesa Biotech, Inc. (EDSA)
CIK:        0001540159
Form:       8-K
Filed at:   2026-08-20T20:15:17+00:00
Accession:  0001171843-26-005686
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edesa Biotech prices $25.0M public offering of shares and warrants
------------------------------------------------------------------

- Offering: 3,870,500 common shares plus warrants and 675,000 pre-funded warrants; combined price $5.50 per share/warrant unit.
- Gross proceeds ~$25.0M, net ~$23.1M after fees; expected close Aug 21, 2026.
- Common share warrants exercisable at $7.50, expire 18 months or 30 days after Phase 2 vitiligo topline data for EB06.
- Underwriters granted 30-day option for 681,825 additional shares and warrants.
- Proceeds for general corporate purposes incl. working capital, R&D and manufacturing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1540159/000117184326005686/0001171843-26-005686-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1540159/000117184326005686/f8k_081726.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-005686

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer